Pharmacokinetic Interactions and Safety Between Exforge Tab. and Crestor Tab. in Healthy Male Subjects

NCT ID: NCT02060019

Last Updated: 2016-12-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 57 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-03-31
• Study Completion Date: 2014-12-31

Brief Summary

This study is designated to evaluate the pharmacokinetic interactions of amlodipine besylate, valsartan and rosuvastatin in healthy male volunteers.

Conditions

Healthy

Keywords

Pharmacokinetics; Pharmacodynamics; Safety; Tolerability

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

exforge 10/160mg(amlodipine 10mg, valsartan160mg)

1 tablet daily for 10days

Group Type: EXPERIMENTAL

administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.

Intervention Type: DRUG

crestor 20mg(rosuvastatin 20mg)

1 tablet daily for 7days

Group Type: EXPERIMENTAL

administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.

Intervention Type: DRUG

Interventions

administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male volunteers in the age between 20 and 55 years old

2. The weight range is not exceed ±20% of ideal weight Ideal weight = [height -100]*0.9

3. Subjects with no history of any significant chronic disease

4. Judged to be in good health on the basis of their electrocardiography (ECG) and routine laboratory data obtained within 3 weeks prior to study drug administration

5. Willing to adhere to protocol requirements and sign a informed consent form

Exclusion Criteria

1. History of clinically significant allergies including drug allergies

2. History of clinically significant hepatic, renal, gastrointestinal, pulmonary, ,musculoskeletal, endocrine, psychiatric, hematologic, oncologic, neurologic or cardiovascular disease

3. History of genetic muscular disease and family history

4. hypotension (Systolic Blood Pressure(SBP) ≤ 105 or Diastolic Blood Pressure(DBP) ≤ 65) or hypertension(SBP ≥ 150 or DBP ≥ 100)

5. AST(Aspartate Transaminase), ALT(ALanine Transaminase), total bilirubin( > 1.5 times to normal range

6. Creatinine clearance < 80mL/min

7. Subjects with a history of gastrointestinal diseases which might significantly change ADME(Absorption, Distribution, Metabolism and Excretion) of medicines

8. Serious injury, surgery and acute illness within 4 weeks prior to drug administration

9. History of alcohol, smoking abuse

• alcohol > 21 units/week, 1 unit=10g=12.5mL of pure alcohol
• smoking > 10 cigarettes/day

10. Use of any other medication, including herbal products, within the 2 weeks before dosing

11. Participated in a previous clinical trial within 3 months prior to drug administration

12. Subjects with whole blood donation within 2 months, component blood donation within months prior to drug administration

13. Special diet known to interfere with the absorption, distribution, metabolism or excretion of drugs (especially, consumption of grapefruit juice) within 7 days prior to drug administration

14. Clinical laboratory test values are positive (HBsAg, HCV Ab, HIV Ag/Ab, VDRL)

15. Subjects considered as unsuitable based on medical judgement by investigators

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

HK inno.N Corporation

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Young Ran Yoon PhD

Role: PRINCIPAL_INVESTIGATOR

Kyungpook university hostipal

Locations

Kyungpook university hospital

Deagu, , South Korea

Countries

South Korea

Other Identifiers

CJ_EXR_101

Identifier Type: -

Identifier Source: org_study_id